Companion Medical erhåller FDA-godkännande
28 juil. 2016 02h30 HE
|
Diamyd Medical AB (publ)
Diamyd Medical (Nasdaq Stockholm First North, DMYD B) meddelar idag att
Companion Medical, Inc. erhåller 510(k)-godkännande från den amerikanska
läkemedelsmyndigheten FDA för sitt InPen®-system, ett...
Companion Medical receives FDA clearance
28 juil. 2016 02h30 HE
|
Diamyd Medical AB (publ)
Diamyd Medical (Nasdaq Stockholm First North, DMYD B) announced today that
Companion Medical,Inc receives 510(k) clearance from the FDA for the InPen®
system, an intelligent insulin administration...
Diamyd Medical och UCLA tar ytterligare steg i utvecklingen av terapi för typ 1-diabetes
18 juil. 2016 02h30 HE
|
Diamyd Medical AB (publ)
Diamyd Medical (Nasdaq Stockholm First North, Ticker: DMYD B) meddelade idag att
Diamyd Medical har kommit överens om att ta ytterligare steg vad gäller
utvecklingen av sin Antigen-Baserade Teknologi...
Diamyd Medical and UCLA advances therapeutic development for type 1 diabetes
18 juil. 2016 02h30 HE
|
Diamyd Medical AB (publ)
Diamyd Medical (Nasdaq Stockholm First North, Ticker: DMYD B) announced today
that Diamyd Medical has agreed to further advance its Antigen Based Technology
together with researchers at the University...
Diamyd Medical informerar om förändringar i intressebolaget Cellaviva
29 juin 2016 02h32 HE
|
Diamyd Medical AB (publ)
Diamyd Medical (Nasdaq Stockholm First North, DMYD B) meddelar att
stamcellsbolaget Cellaviva AB refinansieras med cirka 8,2 MSEK genom
konvertering av ett konvertibellån om cirka 2,7 MSEK och ett...
Diamyd Medical provides information regarding changes in associated company Cellaviva
29 juin 2016 02h32 HE
|
Diamyd Medical AB (publ)
Diamyd Medical (Nasdaq Stockholm First North, DMYD B) announces that the stem
cell company Cellaviva AB is to be refinanced by approximately MSEK 8.2 through
the exercise of a convertible loan of...
Delårsrapport III 15/16
29 juin 2016 02h30 HE
|
Diamyd Medical AB (publ)
september 2015 – maj 2016, Diamyd Medical AB (publ), räkenskapsåret 2015/2016
Tredje kvartalet, 1 mars 2016 – 31 maj 2016
· Periodens resultat uppgick till -18,2 (-7,3) MSEK, varav nedskrivning...
Quarterly Report III 15/16
29 juin 2016 02h30 HE
|
Diamyd Medical AB (publ)
September 2015 – May 2016, Diamyd Medical AB (publ), Fiscal year 2015/2016
Reporting period, Mar 1, 2016 – May 31, 2016
· Net result amounted to MSEK -18.2 (-7.3), of which impairment of holding...
Diamyd Medical’s associated company Cellaviva withdraws new share issue
02 juin 2016 02h30 HE
|
Diamyd Medical AB (publ)
Diamyd Medical (Nasdaq Stockholm First North, DMYD B) announces that its
associated company Cellaviva has withdrawn a new share issue due to low
participation in the issue.
The issue was contingent...
Diamyd Medicals intressebolag Cellaviva drar tillbaka nyemission
02 juin 2016 02h30 HE
|
Diamyd Medical AB (publ)
Diamyd Medical (Nasdaq Stockholm First North, DMYD B) meddelar att
intressebolaget Cellaviva dragit tillbaka en nyemission på grund av för lågt
deltagande i emissionen.
Emissionen var villkorad av att...